27-Feb-2026
Prothena Announces $100 Million Share Repurchase Program
TipRanks (Fri, 27-Feb 5:42 PM ET)
Prothena authorizes up to $100 million share repurchase plan
Seeking Alpha News (Fri, 27-Feb 4:24 PM ET)
Prothena Announces up to $100 Million Share Repurchase Plan
Business Wire (Fri, 27-Feb 4:15 PM ET)
Business Wire (Thu, 19-Feb 4:05 PM ET)
Prothena to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026
Business Wire (Thu, 12-Feb 4:05 PM ET)
Prothena Announces Board of Directors Update
Business Wire (Fri, 12-Dec 4:05 PM ET)
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.
Prothena PLC - trades on the NASDAQ stock market under the symbol PRTA.
As of February 27, 2026, PRTA stock price climbed to $8.67 with 334,042 million shares trading.
PRTA has a beta of 0.72, meaning it tends to be less sensitive to market movements. PRTA has a correlation of 0.04 to the broad based SPY ETF.
PRTA has a market cap of $466.68 million. This is considered a Small Cap stock.
Last quarter Prothena PLC - reported $21,000 in Revenue and -$.40 earnings per share. This fell short of revenue expectation by $-5 million and exceeded earnings estimates by $.05.
In the last 3 years, PRTA traded as high as $79.65 and as low as $4.32.
The top ETF exchange traded funds that PRTA belongs to (by Net Assets): XBI, IWM, VXF, IWN, IBB.
PRTA has underperformed the market in the last year with a price return of -42.7% while the SPY ETF gained +18.5%. PRTA has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -16.9% and -3.2%, respectively, while the SPY returned +1.2% and +0.6%, respectively.
PRTA support price is $8.30 and resistance is $8.98 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PRTA shares will trade within this expected range on the day.
